---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-24-000017"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2024-02-23T23:59:59+00:00"
generated_at: "2026-06-05T17:07:42.257442+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Salarius extends cash runway into H1 2025; CEO Arthur transitions to part-time consultant

## Summary
- CEO David Arthur ends full-time employment; becomes part-time consultant effective Feb 20, 2024, at $10,417/month.
- Cash runway expected to extend into first half of 2025 due to cost-saving measures including reduced director pay and operating expenses.
- Ongoing strategic review with Canaccord Genuity to maximize shareholder value; clinical trials in hematologic cancers and Ewing sarcoma continue.
- Clinical data: 50% ORR in hematologic cancers (MDACC trial) and 60% ORR in first-relapse Ewing sarcoma patients with seclidemstat combinations.

## SEC filing metadata
- accession: 0001615219-24-000017
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2024-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000017/0001615219-24-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000017/flks-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-24-000017
- JSON: https://secwatch.observer/filing/0001615219-24-000017.json
- Plain text: https://secwatch.observer/filing/0001615219-24-000017.txt

## Key facts
- Executive change
  David J. Arthur changed role as President and Chief Executive Officer at Decoy Therapeutics Inc..
  - Action: transitioned to part-time consultant
  - Role: President and Chief Executive Officer
  source text: On February 20, 2024 (the “Separation Date”), Salarius Pharmaceuticals, Inc. (the “Company”) entered into a separation and release agreement (the “Separation Agreement”) with David J. Arthur, the Company’s President and Chief Executive Officer, which provides for Mr. Arthur’s separation of employment, effective as of the Separation Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000017/0001615219-24-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.